Selective Precision Targeting (SPoT)
ID: 359852Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/359852
Timeline
    Description

    The National Institutes of Health (NIH) is offering a federal grant opportunity titled Selective Precision Targeting (SPoT) aimed at advancing therapeutic drug delivery systems to specific hard-to-reach locations within the human body. This initiative seeks to optimize the targeting of nanoparticle therapeutics, assess biodistribution and off-target effects, provide evidence of functional cargo activity, and determine the optimal route of administration using microphysiological systems. With an estimated total program funding of $1.5 million and the expectation of awarding five grants, eligible small businesses are encouraged to apply. Interested applicants can reach out to Dr. Passley Hargrove-Grimes at passley.hargrove@nih.gov or by phone at 240-485-4149, with proposals due by February 17, 2026, and project start anticipated on January 18, 2027.

    Point(s) of Contact
    Passley Hargrove-Grimes, Ph.D. National Center for Advancing Translational Sciences (NCATS)
    (240) 485-4149
    passley.hargrove@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Forecast for Expanding the Target Landscape by Drugging the Undruggable (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity titled "Forecast for Expanding the Target Landscape by Drugging the Undruggable (R21 Clinical Trial Not Allowed)," aimed at small businesses engaged in innovative research on undruggable target classes associated with intractable human diseases. The initiative seeks applications that propose methods or agents capable of selectively modulating traditionally undruggable targets, such as intrinsically disordered proteins and RNA, through preclinical proof of concept studies. This funding is critical for advancing therapeutic strategies for diseases that are challenging to treat with conventional therapies. The estimated total program funding is $1,000,000, with three awards expected, and interested applicants should prepare for the application process, which is anticipated to open with a synopsis posted on August 15, 2025, and close on October 16, 2025. For further inquiries, potential applicants can contact Dr. Karlie Sharma at Karlie.sharma@nih.gov or by phone at 240-381-3118.
    NIGMS National and Regional Resources
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "NIGMS National and Regional Resources," aimed at supporting resources that enhance biomedical research capabilities for a large number of investigators. This program seeks to provide access to state-of-the-art technologies and expertise, enabling substantial numbers of researchers to benefit from resources that may not be available at individual institutions. The grant is open to small businesses, with no cost-sharing or matching requirements, and is categorized under discretionary funding with an estimated award date of June 1, 2026. Interested applicants can reach out to Han Nguyen, Ph.D., at han.nguyen@nih.gov or call 301-594-4640 for further information, and should note that the application period will close on September 25, 2025.
    Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the Blueprint Neurotherapeutics Network (BPN) for Biologics, aimed at supporting biologic-based drug discovery and development for disorders of the nervous system. This initiative invites applications from U.S.-based small businesses to develop diverse therapeutic modalities, including antibodies and gene therapies, with a focus on specific nervous system disorders and a requirement for preliminary data demonstrating efficacy. The program emphasizes a phased, milestone-driven cooperative agreement, facilitating the transition of promising biotherapeutics from lead optimization to first-in-human trials while ensuring regulatory compliance and effective intellectual property management. Applications are due by January 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-294.html.
    Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe)" aimed at advancing research on extracellular vesicles (EVs) as therapeutics in regenerative medicine. This cooperative agreement seeks to support the translation of EV-based therapeutics, focusing on their role in intercellular communication and potential applications in tissue repair and regeneration. Eligible applicants for this discretionary funding opportunity include small businesses, with no cost-sharing or matching requirements. Interested parties should note that the estimated synopsis post date is October 15, 2025, with a closing date of February 17, 2026, and an anticipated award date of December 17, 2026. For further inquiries, applicants can contact Christine Happel, Ph.D., at christine.happel@nih.gov or by phone at 240-472-7550.
    NIH Director’s Transformative Research Awards (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to announce the NIH Director’s Transformative Research Awards, a federal grant opportunity aimed at supporting innovative and unconventional research projects. This program encourages individual scientists or collaborative teams to propose groundbreaking research that has the potential to redefine scientific paradigms or develop transformative technologies, without the need for preliminary data or detailed experimental plans. With an estimated total funding of $8 million and the expectation of awarding seven grants, interested applicants should prepare their proposals in advance, as applications will be solicited starting June 20, 2025, with a closing date of September 3, 2025. For further inquiries, potential applicants can contact Dr. Patricia Labosky at TransformativeAwards@mail.nih.gov or by phone at 301-594-4863.
    Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI), aimed at supporting advanced pre-clinical research in nanotechnology-based cancer diagnostics and therapeutics. This initiative encourages innovative projects that utilize nanoparticle formulations or nano-devices to address significant clinical objectives in cancer treatment, with a focus on enhancing treatment efficacy through combination therapies and immunotherapy. Funding is available up to $475,000 annually for a maximum of four years, with applications accepted from eligible institutions including higher education entities, nonprofits, and government organizations. Interested applicants should refer to the detailed application process outlined on Grants.gov and the NIH ASSIST system, with key deadlines spanning from April 2025 to November 2027. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Expanding the Target Landscape by Drugging the Undruggable (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Expanding the Target Landscape by Drugging the Undruggable," aimed at supporting exploratory projects that target currently undruggable protein classes associated with intractable human diseases. Applicants are required to identify a relevant undruggable target class and propose innovative preclinical methods or agents to address treatment gaps, with a focus on developing strategies that cannot be tackled by existing therapeutic approaches. This initiative is crucial for advancing translational science and improving public health outcomes by fostering the development of novel treatments for conditions that currently lack effective therapies. Up to $275,000 is available for projects over a two-year period, with applications due by February 17, 2028. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "NeuroNEXT Small Business Innovation in Clinical Trials," aimed at encouraging small businesses to conduct exploratory clinical trials of investigational agents related to neurological disorders. This initiative seeks applications for Phase II Small Business Innovation Research (SBIR) projects, with a budget of up to $3 million over five years, focusing on trials that align with the strategic plan of the National Institute of Neurological Disorders and Stroke (NINDS). The program is designed to foster public-private partnerships to enhance the development and commercialization of innovative therapies, ultimately improving clinical outcomes in neuroscience research. Interested applicants must adhere to a Community Engagement and Research Inclusion (CERI) plan, with the first application deadline set for January 5, 2025, and additional deadlines throughout 2026 and 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Miniaturization and Automation of Tissue Chip Systems (MATChS) (U43/U44 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "Miniaturization and Automation of Tissue Chip Systems" (MATChS), aimed at advancing the development of automated and miniaturized microphysiological systems (MPS) for drug discovery and biomedical research. This funding opportunity encourages U.S. small business concerns (SBCs) to propose innovative solutions that enhance the efficiency and reliability of tissue chip technologies, with a focus on reducing complexity and costs while facilitating higher throughput. Approximately $2.15 million is allocated for FY 2024 to support projects that collaborate with NIH staff to achieve defined milestones and pathways to commercialization. Interested applicants must submit their proposals by February 23, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Not Allowed) aimed at encouraging United States small business concerns (SBCs) to engage in research and development projects aligned with NIH's mission. Eligible applicants, defined as SBCs by the Small Business Administration, are invited to prepare for future submissions of Phase I, Phase II, Fast-Track, and Phase IIB grant applications, although applications are not currently being solicited. This funding opportunity is significant for fostering innovative health-related research and collaboration among small businesses and NIH institutes. Interested parties can reach out to the NIH SEED Office of Extramural Research at SEEDinfo@nih.gov or by phone at 301-827-8595 for further information, with the estimated synopsis posting date set for October 1, 2025, and a projected award date of June 1, 2026.